# Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects

> **NCT04297865** · PHASE1 · UNKNOWN · sponsor: **HK inno.N Corporation** · enrollment: 55 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** A dose as CJ-15314
- **DRUG:** B dose as CJ-15314
- **DRUG:** C dose as CJ-15314
- **DRUG:** D dose as CJ-15314
- **DRUG:** E dose as CJ-15314
- **DRUG:** F dose as CJ-15314
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04297865
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-24
- **Primary completion:** 2021-01
- **Final completion:** 2021-02
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2020-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04297865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04297865, "Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04297865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*